Science in Sport PLC

Science in Sport PLC

Consumer GoodsFood Producers
  • Price (GBX)72.50
  • Today's Change-2.50 / -3.33%
  • Shares traded85.01k
  • 1 Year change+123.08%
  • Beta0.9964
Data delayed at least 20 minutes, as of Oct 26 2021 16:23 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Science in Sport plc is engaged in developing, manufacturing and marketing sports nutrition products for professional athletes and sports enthusiasts. The Company's product lines include SiS GO isotonic powders and gels, which are digestible carbohydrates for use during exercise; SiS hydration products, which include SiS GO Hydro tablets and SiS GO Electrolyte powders; SiS GO Bars, which include cereal-based food bars; SiS REGO range, which includes drinks and protein bars for recovery after training, and SiS Protein, which is a whey protein range for lean muscle development. The Company offers products in sport categories, including cycling, running, gym, team sports, triathlon and rowing. The Company's products include SiS GO Energy, SiS REGO Rapid Recovery, SiS WHEY20, SiS Whey Protein, SiS GO Isotonic Energy Gel, SiS Elite Team SKY and GO Energy Bar. The Company's subsidiaries include SiS (Science in Sport) Limited, SiS APAC Pty Limited and Science in Sport Inc.

  • Revenue in GBP (TTM)56.04m
  • Net income in GBP-837.00k
  • Incorporated2013
  • Employees197.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Venture Life Group PLC30.08m2.37m56.62m119.0017.020.785312.991.880.02640.02640.3220.57310.43062.474.29252,739.503.390.84943.901.0142.7240.357.871.784.9814.790.1342--48.8527.07161.95--28.44--
Kanabo Group PLC15.00k-2.41m57.22m----8.59--3,814.82-0.0096-0.00960.00010.0180.0039--0.0932---62.27---66.38---26.67---16,046.67--24.36--0.00------63.91------
OKYO Pharma Ltd0.00-3.00m60.67m6.00--10.91-----0.0044-0.00440.000.00570.00----0.00-106.65---157.37-------------3,496.670.0182-------146.83------
C4X Discovery Holdings PLC0.00-7.44m63.79m46.00--3.34-----0.0501-0.05010.000.08390.00----0.00-46.17-75.84-49.92-87.08--99.80---426.65---919.800.0265------28.62---30.28--
Destiny Pharma PLC0.00-5.47m66.45m14.00--6.54-----0.1058-0.10580.000.16980.00----0.00-65.43-40.73-70.34-43.29------------0.00-------14.93--284.88--
Shield Therapeutics PLC1.95m-13.04m77.16m16.00--1.51--39.59-0.0817-0.08170.01220.23630.0430.53481.54121,812.50-28.76-24.56-30.15-27.0361.3189.95-668.91-199.8717.86-451.480.00--1,344.65--70.11---29.49--
Futura Medical plc.0.00-2.93m96.74m13.00--7.45-----0.0117-0.01170.000.04520.00----0.00-34.96-58.52-38.86-74.23-------4,391.3918.60--0.00---100.00--73.00---12.11--
Science in Sport PLC56.04m-837.00k101.33m197.00--2.1141.701.81-0.0061-0.00610.42050.3560.86583.435.11284,446.70-1.29-9.92-1.63-11.7450.9850.27-1.49-12.971.24-6.480.0147---0.43939.7569.24--32.13--
Diurnal Group PLC4.37m-10.05m103.12m36.00--2.73--23.59-0.0733-0.07330.03190.22370.13930.543611.59121,416.70-32.02-43.08-35.86-50.3382.18---229.90-427.579.59--0.00---30.76---146.78------
Verici Dx Plc-100.00bn-100.00bn104.06m8.00------------------------------------------------------------
Skinbiotherapeutics PLC0.00-1.26m104.10m7.00--17.35-----0.0096-0.00960.000.03830.00----0.00-26.74---27.90--------------0.00-------30.66------
Yourgene Health PLC18.29m-12.18m108.57m180.00--3.29--5.94-0.0173-0.01730.02670.04550.42143.413.34101,600.20-28.07-24.79-34.05-33.6962.2057.85-66.62-53.901.46-20.970.1281--10.0849.46-400.58--27.36--
4d Pharma PLC490.00k-67.69m115.75m115.00--2.92--236.23-0.4438-0.44380.00340.220.0112--0.1954,260.87-154.55-32.46-182.79-35.41-----13,813.67-13,963.364.18-54.630.0248--153.08---7.88---27.01--
Data as of Oct 26 2021. Currency figures normalised to Science in Sport PLC's reporting currency: UK Pound GBX

Institutional shareholders

75.95%Per cent of shares held by top holders
HolderShares% Held
Aviva Investors Global Services Ltd.as of 31 Dec 202014.62m10.82%
Otus Capital Management Ltd.as of 17 Mar 202114.11m10.45%
BennBridge Ltd.as of 04 Feb 202113.42m9.93%
Legal & General Investment Management Ltd.as of 29 Oct 202013.00m9.62%
J.O. Hambro Capital Management Ltd.as of 06 Oct 202112.18m9.01%
River & Mercantile Asset Management LLPas of 31 Dec 202011.11m8.23%
Schroder Investment Management Ltd.as of 17 Jun 20216.77m5.01%
Sarasin & Partners LLPas of 29 Jan 20216.77m5.01%
AXA Investment Managers UK Ltd.as of 31 Aug 20215.78m4.28%
Burgundy Asset Management Ltd.as of 31 Aug 20214.85m3.59%
More ▼
Data from 31 Mar 2021 - 12 Oct 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.